GLG News by General Cardiologists (US)

“A requirement for demonstrating cardiovascular benefit will likely have major implications on the availability of new treatments for type 2 diabetes, because conclusive evidence of a reduced risk of macrovascular complications in type 2 diabetes has not yet been established for any of the currently...

More than 50% of patients have the 3 ccomponents to qualify for diagnosis of Metabolic Syndrome.Twwo of the components,Diabetes and Obesity are present in 20-25% of them and are difficult to control.Exenatide seems to provide that benefit.

Once again we are finding that traditional Chinese medicine is just as affective in this day and time as it was back during the Tang Dynasty.  Even then, Chinese red yeast rice was known to 'remove blockages' and aid in digestion.  What is even more exciting in this study,...

Third party payers benefit the most from EHRs because it makes charts easier to audit   The cost of implementing an EHR is excessive for a small practice of 2-5 physicians.

1.  Beta Blockers are now implicated in negative outcomes for some non-cardiac surgical patients. 2.  The POISE Trial is probably teaching us that vasoactive medications need to be utilized judiciously, given to many, but not all surgical patients. 3.  The POISE Trial results conflict...

The info that tekturna HCT works twice as well as HCTZ alone is not earth shattering.  Of course it's better.  That can be said of any HCT/medicine combination

I am a heavy user of ARB's and Tekturna.  This article does not really show anything of significance.  Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...

Regadenoson is similar to the drug it's set to replace, adenosine, in terms of its ability to increase coronary flow and detect coronary artery disease. However, it's easier to use (it's given as a bolus as opposed to an infusion over 3-5 minutes) and seems to have less side effects. It also has a longer...

The treatment of hyperlipidemia has profound repercussions on cardiovascular disease. The market is huge. I hear that there were 35 million prescriptions for ezetimibe products last year. Although the epidemiological association between LDL and cardiac risk is strong, LDL is an imperfect surrogate for...

The decision by Takeda to halt development of TAK-475, is not surprising considering the problems faced now by companies trying to get regulatory approval for new lipid-lowering drugs. TAK-475 was not more potent, but was thought to have a better safety profile than statins. However, because the safety...